{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:02:59Z","timestamp":1784595779694,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Baseline CD20 expression\u2009\u2265\u200920% in B-cell acute lymphoblastic leukemia (B-ALL) has been associated with poorer outcomes, which improved after rituximab introduction into frontline therapy for CD20-positive cases. We investigated the clinical and biological significance of this threshold by monitoring early dynamics of CD20 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In the GMALL 08\/2013 trial, adults with B-ALL received a cyclophosphamide\/dexamethasone prephase, followed by Induction and Consolidation I, which included four rituximab doses in\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      -negative patients, irrespective of CD20 status. CD20 expression was measured by standardized multiparametric flow cytometry in 274 patients in bone marrow and blood at diagnosis and in blood after prephase. IG\/TR based measurable residual disease (MRD) was correlated with baseline bone marrow or the highest CD20-positive blast percentage recorded throughout prephase. The historical GMALL 07\/2003 cohort treated without rituximab served for comparison.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline CD20 expression was significantly higher in blood than in bone marrow and increased further during prephase. In paired baseline samples, 6\/76 c-\/pre-B ALL cases (7.9%) were CD20-negative by bone marrow (&lt;\u200920%) but positive in blood. In paired blood samples, 14\/106 patients crossed the 20% threshold after prephase (12\/86 c-\/pre-B ALL, 13.9% and 2\/20 pro-B ALL, 10.0%). Among 182\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      -negative patients, highest recorded CD20 across all time points classified 76 (41.8%) as &lt;\u200920% and 106 (58.2%) as \u2265\u200920%. Higher CD20 expression was associated with improved MRD response under rituximab. Among MRD-evaluable patients after Induction I (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009161), molecular complete remission (MolCR) was achieved in 10.6% of patients with CD20 expression\u2009&lt;\u200920% compared with 30.5% of those with CD20 expression\u2009\u2265\u200920%. After Consolidation I (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009159), corresponding MolCR rates were 50.0% and 72.6%, respectively. Associations were weaker when only baseline CD20 bone marrow status was considered. No association with MRD response was observed in GMALL 07\/2003 patients treated without rituximab, suggesting a treatment-driven effect in GMALL 08\/2013.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CD20 expression in adult B-ALL varies from diagnostic bone marrow to blood and post-prephase measurements. The highest recorded CD20% value better predicts early MRD responses under rituximab. Post-prephase CD20 reassessment in blood identifies additional patients with eligibility for rituximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registry<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, TRN: NCT02881086 (2016-08-23); NCT00198991 (2005-09-12).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-026-01832-4","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:55:03Z","timestamp":1784530503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-8880","authenticated-orcid":false,"given":"Monika","family":"Szczepanowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Bendig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Beder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guranda","family":"Chitadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kotrov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Faul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"G\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Kehden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria Murga","family":"Penas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ritgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Trautmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Burmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1832_CR1","doi-asserted-by":"publisher","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 D. 346:235\u201342. https:\/\/doi.org\/10.1056\/NEJMoa011795. Cited in: PMID: 11807147.","DOI":"10.1056\/NEJMoa011795"},{"key":"1832_CR2","doi-asserted-by":"crossref","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998 D. 16:2825\u201333 .2825. Cited in: PMID: 9704735.","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"1832_CR3","doi-asserted-by":"crossref","unstructured":"Czuczman MS, Grillo-L\u00f3pez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999 A.D.; 17:268\u2013276. doi: 10.1200\/JCO.1999.17.1.268. Cited in: PMID: 10458242.","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"1832_CR4","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","volume":"113","author":"DA Thomas","year":"2009","unstructured":"Thomas DA, O\u2019Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113:6330\u20137. https:\/\/doi.org\/10.1182\/blood-2008-04-151860 Cited. In PMID: 18703706.","journal-title":"Blood."},{"key":"1832_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3324\/haematol.2011.054064","volume":"97","author":"F Mannelli","year":"2012","unstructured":"Mannelli F, Gianfaldoni G, Intermesoli T, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Pogliani EM, Fumagalli M, Angelucci E, et al. CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: New insights from the molecular study of minimal residual disease. Haematologica. 2012;97:568\u201371. https:\/\/doi.org\/10.3324\/haematol.2011.054064 Cited. In PMID: 22058217.","journal-title":"Haematologica."},{"key":"1832_CR6","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","volume":"28","author":"DA Thomas","year":"2010","unstructured":"Thomas DA, O\u2019Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.26.9456 Cited. In PMID: 20660823.","journal-title":"J Clin Oncol."},{"key":"1832_CR7","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532\u201343. https:\/\/doi.org\/10.1200\/JCO.2010.30.1382 Cited. In PMID: 21220592.","journal-title":"J Clin Oncol."},{"key":"1832_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/CCO.0000000000000009","volume":"25","author":"D Hoelzer","year":"2013","unstructured":"Hoelzer D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25:701\u20136. https:\/\/doi.org\/10.1097\/CCO.0000000000000009 Cited. In PMID: 24097105.","journal-title":"Curr Opin Oncol."},{"key":"1832_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","volume":"375","author":"S Maury","year":"2016","unstructured":"Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375:1044\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1605085 Cited. In PMID: 27626518.","journal-title":"N Engl J Med."},{"key":"1832_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood.V116.21.170.170","volume":"116","author":"D Hoelzer","year":"2010","unstructured":"Hoelzer D, Huettmann A, Kaul F, Irmer S, Jaekel N, Mohren M, Lipp T, Wedelin K, de Valle F, Schmid M. Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20\u2009+\u2009B-Lineage Standard and High Risk Patients; Results of 263 CD20\u2009+\u2009Patients Studied Prospectively In GMALL Study 07\/2003. Blood. 2010;116:170. https:\/\/doi.org\/10.1182\/blood.V116.21.170.170.","journal-title":"Blood"},{"key":"1832_CR11","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S2352-3026(22)00038-2.","volume":"9","author":"DI Marks","year":"2022","unstructured":"Marks DI, Kirkwood AA, Rowntree CJ, Aguiar M, Bailey KE, Beaton B, Cahalin P, Castleton AZ, Clifton-Hadley L, Copland M, et al. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): A phase 3, multicentre, randomised controlled trial. Lancet Haematol. 2022;9:e262\u201375. https:\/\/doi.org\/10.1016\/S2352-3026(22)00038-2. Cited. In PMID: 35358441.","journal-title":"Lancet Haematol."},{"key":"1832_CR12","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","volume":"112","author":"MN Dworzak","year":"2008","unstructured":"Dworzak MN, Schumich A, Printz D, P\u00f6tschger U, Husak Z, Attarbaschi A, Basso G, Gaipa G, Ratei R, Mann G, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112:3982\u20138. https:\/\/doi.org\/10.1182\/blood-2008-06-164129 Cited. In PMID: 18780832.","journal-title":"Blood."},{"key":"1832_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/sj.leu.2403559","volume":"19","author":"G Gaipa","year":"2005","unstructured":"Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, Bugarin C, Veltroni M, Michelotto B, Ratei R, et al. Drug-induced immunophenotypic modulation in childhood ALL: Implications for minimal residual disease detection. Leukemia. 2005;19:49\u201356. https:\/\/doi.org\/10.1038\/sj.leu.2403559 Cited. In PMID: 15538405.","journal-title":"Leukemia."},{"key":"1832_CR14","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, Fo\u00e0 R, Giebel S, Hoelzer D, Hunault M, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1891\u2013902. https:\/\/doi.org\/10.1182\/blood.2023020794 Cited. In PMID: 38295337.","journal-title":"Blood."},{"key":"1832_CR15","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, Fo\u00e0 R, Giebel S, Hoelzer D, Hunault M, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1903\u201330. https:\/\/doi.org\/10.1182\/blood.2023023568 Cited. In PMID: 38306595.","journal-title":"Blood."},{"key":"1832_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1182\/blood-2021-146306","volume":"138","author":"N Goekbuget","year":"2021","unstructured":"Goekbuget N, Stelljes M, Viardot A, Nachtkamp K, Steffen B, Schneller F, Alakel N, Topp M, B\u00f6ll B, Faul C, et al. First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08\/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia\/Lymphoma (ALL\/LBL). Blood. 2021;138:362. https:\/\/doi.org\/10.1182\/blood-2021-146306.","journal-title":"Blood"},{"key":"1832_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1182\/blood-2023-179442","volume":"142","author":"N Goekbuget","year":"2023","unstructured":"Goekbuget N, Steffen B, Nachtkamp K, B\u00f6ll B, Buecklein VL, Faul C, Panse J, R\u00f6llig C, Schneller F, Spriewald B, et al. CNS Irradiation in Adult De Novo B-Precursor ALL \/ Lbl: Results of the Randomized GMALL T rial 08\/2013 Indicate Potential Antileukemic Efficacy. Blood. 2023;142:828. https:\/\/doi.org\/10.1182\/blood-2023-179442.","journal-title":"Blood"},{"key":"1832_CR18","doi-asserted-by":"publisher","unstructured":"Pfeifer H, Lang F, Fiedler W, Stelljes M, Schneller F, Steffen B, B\u00f6ll B, Viardot A, Faul C, Lars Teichmann L et al. P355: Favorable outcome of Philadelphia-positive acute lymphoblastic leukemia with imatinib, dose-reduced induction followed by allogeneic stem cell transplantation \u2013 results from the GMALL trial 08\/13. Hemasphere. 2023; 7. https:\/\/doi.org\/10.1097\/01.HS9.0000968332.33834.d6","DOI":"10.1097\/01.HS9.0000968332.33834.d6"},{"key":"1832_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.07.013","volume":"475","author":"H Glier","year":"2019","unstructured":"Glier H, Heijnen I, Hauwel M, Dirks J, Quarroz S, Lehmann T, Rovo A, Arn K, Matthes T, Hogan C, et al. Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland. J Immunol Methods. 2019;475: 112348. https:\/\/doi.org\/10.1016\/j.jim.2017.07.013 Cited. In PMID: 28760670.","journal-title":"J Immunol Methods."},{"key":"1832_CR20","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, B\u00f6ttcher S, Ritgen M, Almeida J, Lhermitte L, Asnafi V, Mendon\u00e7a A, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986\u20132010. https:\/\/doi.org\/10.1038\/leu.2012.122 Cited. In PMID: 22948490.","journal-title":"Leukemia."},{"key":"1832_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.11.007","volume":"475","author":"M Nov\u00e1kov\u00e1","year":"2019","unstructured":"Nov\u00e1kov\u00e1 M, Glier H, Brdi\u010dkov\u00e1 N, Vlkov\u00e1 M, Santos AH, Lima M, Roussel M, Flores-Montero J, Szczepanski T, B\u00f6ttcher S, et al. How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. J Immunol Methods. 2019;475: 112388. https:\/\/doi.org\/10.1016\/j.jim.2017.11.007 Cited. In PMID: 29154914.","journal-title":"J Immunol Methods."},{"key":"1832_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.112680","volume":"475","author":"H Glier","year":"2019","unstructured":"Glier H, Novakova M, Te Marvelde J, Bijkerk A, Morf D, Thurner D, Rejlova K, Lange S, Finke J, van der Sluijs-Gelling A, et al. Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instruments. J Immunol Methods. 2019;475: 112680. https:\/\/doi.org\/10.1016\/j.jim.2019.112680 Cited. In PMID: 31655051.","journal-title":"J Immunol Methods."},{"key":"1832_CR23","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJM van Dongen","year":"2012","unstructured":"van Dongen JJM, Lhermitte L, B\u00f6ttcher S, Almeida J, van der Velden VHJ, Flores-Montero J, Rawstron A, Asnafi V, L\u00e9crevisse Q, Lucio P, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908\u201375. https:\/\/doi.org\/10.1038\/leu.2012.120 Cited. In PMID: 22552007.","journal-title":"Leukemia."},{"key":"1832_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.leu.2401831","volume":"14","author":"M Br\u00fcggemann","year":"2000","unstructured":"Br\u00fcggemann M, Droese J, Bolz I, L\u00fcth P, Pott C, von Neuhoff N, Scheuering U, Kneba M. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia. 2000;14:1419\u201325. https:\/\/doi.org\/10.1038\/sj.leu.2401831 Cited. In PMID: 10942238.","journal-title":"Leukemia."},{"key":"1832_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VHJ van der Velden","year":"2007","unstructured":"van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311. https:\/\/doi.org\/10.1038\/sj.leu.2404586 Cited. In PMID: 17287850.","journal-title":"Leukemia."},{"key":"1832_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-59745-418-6_7","volume":"538","author":"VHJ van der Velden","year":"2009","unstructured":"van der Velden VHJ, van Dongen JJM. MRD detection in acute lymphoblastic leukemia patients using Ig\/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol. 2009;538:115\u201350https:\/\/doi.org\/10.1007\/978-1-59745-418-6_7 Cited. In PMID: 19277574.","journal-title":"Methods Mol Biol."},{"key":"1832_CR27","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1182\/bloodadvances.2021006727","volume":"6","author":"M Kotrov\u00e1","year":"2022","unstructured":"Kotrov\u00e1 M, Koopmann J, Trautmann H, Alakel N, Beck J, Nachtkamp K, Steffen B, Raffel S, Viardot A, Wethmar K, et al. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Blood Adv. 2022;6:3006\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2021006727 Cited. In PMID: 35026836.","journal-title":"Blood Adv."},{"key":"1832_CR28","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1038\/s41375-019-0430-z","volume":"33","author":"L Bastian","year":"2019","unstructured":"Bastian L, Schroeder MP, Eckert C, Schlee C, Tanchez JO, K\u00e4mpf S, Wagner DL, Schulze V, Isaakidis K, L\u00e1zaro-Navarro J, et al. PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. Leukemia. 2019;33:1895\u2013909. https:\/\/doi.org\/10.1038\/s41375-019-0430-z Cited. In PMID: 30842609.","journal-title":"Leukemia."},{"key":"1832_CR29","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s41375-022-01557-6","volume":"36","author":"L Bastian","year":"2022","unstructured":"Bastian L, Hartmann AM, Beder T, H\u00e4nzelmann S, K\u00e4ssens J, Bultmann M, Hoeppner MP, Franzenburg S, Wittig M, Franke A, et al. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment. Leukemia. 2022;36:1676\u201380. https:\/\/doi.org\/10.1038\/s41375-022-01557-6 Cited. In PMID: 35397658.","journal-title":"Leukemia."},{"key":"1832_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000939","volume":"7","author":"T Beder","year":"2023","unstructured":"Beder T, Hansen B-T, Hartmann AM, Zimmermann J, Amelunxen E, Wolgast N, Walter W, Zaliova M, Anti\u0107 \u017d, Chouvarine P, et al. The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age. Hemasphere. 2023;7: e939. https:\/\/doi.org\/10.1097\/HS9.0000000000000939 Cited. In PMID: 37645423.","journal-title":"Hemasphere."},{"key":"1832_CR31","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2021","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria.: R Foundation for Statistical Computing; 2021."},{"key":"1832_CR32","doi-asserted-by":"publisher","unstructured":"Novakova M, Zaliova M, Fiser K, Vakrmanova B, Slamova L, Musilova A, Br\u00fcggemann M, Ritgen M, Fronkova E, Kalina T et al. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch. Haematologica. Epub ahead of print. https:\/\/doi.org\/10.3324\/haematol.2020.250423. Cited in: PMID: 32646889.","DOI":"10.3324\/haematol.2020.250423"},{"key":"1832_CR33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/leu.2013.354","volume":"28","author":"L Slamova","year":"2014","unstructured":"Slamova L, Starkova J, Fronkova E, Zaliova M, Reznickova L, van Delft FW, Vodickova E, Volejnikova J, Zemanova Z, Polgarova K, et al. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. Leukemia. 2014;28:609\u201320. https:\/\/doi.org\/10.1038\/leu.2013.354 Cited. In PMID: 24270736.","journal-title":"Leukemia."},{"key":"1832_CR34","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1182\/blood.2023021952","volume":"143","author":"B Buldini","year":"2024","unstructured":"Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Br\u00fcggemann M, Mejstrikova E, Cazzaniga G, Hrusak O, Szczepanowski M, et al. CD371-positive pediatric B-cell acute lymphoblastic leukemia: Propensity to lineage switch and slow early response to treatment. Blood. 2024;143:1738\u201351. https:\/\/doi.org\/10.1182\/blood.2023021952 Cited. In PMID: 38215390.","journal-title":"Blood."},{"issue":"949\u201371","key":"1832_CR35","doi-asserted-by":"publisher","first-page":"v","DOI":"10.1016\/j.hoc.2009.07.005","volume":"23","author":"DA Thomas","year":"2009","unstructured":"Thomas DA, O\u2019Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23(949\u201371):v. https:\/\/doi.org\/10.1016\/j.hoc.2009.07.005 Cited. In PMID: 19825447.","journal-title":"Hematol Oncol Clin North Am."},{"key":"1832_CR36","unstructured":"Thomas DA. Rituximab as therapy for acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2010; 8:168\u201371. Cited in: PMID: 20400931."},{"key":"1832_CR37","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O\u2019Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569\u201380. https:\/\/doi.org\/10.1002\/cncr.21776 Cited. In PMID: 16502413.","journal-title":"Cancer."},{"key":"1832_CR38","doi-asserted-by":"publisher","unstructured":"Serbanica AN, Popa DC, Caruntu C, Pasca S, Scheau C, Serbanica IV, Suciu R, Tica V, Busescu E, Cima LN et al. The Significance of CD20 Intensity Variance in Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Med. 2023; 12. https:\/\/doi.org\/10.3390\/jcm12041451. Cited in: PMID: 36835986.","DOI":"10.3390\/jcm12041451"},{"key":"1832_CR39","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695.","volume":"123","author":"K Beldjord","year":"2014","unstructured":"Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland M-L, Leguay T, Thomas X, Cayuela J-M, Grardel N, Chalandon Y, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739\u201349. https:\/\/doi.org\/10.1182\/blood-2014-01-547695. Cited. In PMID: 24740809.","journal-title":"Blood."},{"key":"1832_CR40","doi-asserted-by":"publisher","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, Wood BL, Kelloff GJ, Jessup JM, Radich JP. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol. 2017; 3. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0580. Cited in: PMID: 28494052.","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"1832_CR41","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","volume":"61","author":"N G\u00f6kbuget","year":"2020","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, Faul C, Br\u00fcggemann M, Taylor K, Mergen N, et al. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61:2665\u201373. https:\/\/doi.org\/10.1080\/10428194.2020.1780583 Cited. In PMID: 32619115.","journal-title":"Leuk Lymphoma."},{"key":"1832_CR42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3324\/haematol.2009.010306","volume":"95","author":"S Maury","year":"2010","unstructured":"Maury S, Huguet F, Leguay T, Lacombe F, Maynadi\u00e9 M, Girard S, de Labarthe A, Kuhlein E, Raffoux E, Thomas X, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95:324\u20138. https:\/\/doi.org\/10.3324\/haematol.2009.010306 Cited. In PMID: 19773266.","journal-title":"Haematologica."},{"key":"1832_CR43","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1182\/blood-2024-209438","volume":"144","author":"DJ DeAngelo","year":"2024","unstructured":"DeAngelo DJ, Yin J, Advani AS, Luger S, Fulcher J, Liedtke M, Uy GL, Dinner SN, Wilde L, Luskin MR, et al. Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial. Blood. 2024;144:308. https:\/\/doi.org\/10.1182\/blood-2024-209438.","journal-title":"Blood"},{"key":"1832_CR44","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1016\/S2352-3026(20)30144-7.","volume":"7","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, et al. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: A single-arm, phase 2 trial. Lancet Haematol. 2020;7:e523-33. https:\/\/doi.org\/10.1016\/S2352-3026(20)30144-7. Cited. In PMID: 32589978.","journal-title":"Lancet Haematol."},{"key":"1832_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3445","volume":"18","author":"M Zhu","year":"2025","unstructured":"Zhu M, Guan X, Ganguly S, Welf E, Davis JD. CD20\u00d7CD3 Bispecific Antibodies in B-NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research. Clin Transl Sci. 2025;18: e70250. https:\/\/doi.org\/10.1002\/cpt.3445 Cited. In PMID: 40471801.","journal-title":"Clin Transl Sci."},{"key":"1832_CR46","doi-asserted-by":"publisher","unstructured":"Prica A, Roschewski M, Beale P, Pittaluga S, Delabie J, Ortega C, Kridel R. Glofitamab with Polatuzumab Vedotin in Refractory Burkitt\u2019s Lymphoma. N Engl J Med 2025 D. 392:1760\u20132. https:\/\/doi.org\/10.1056\/NEJMc2501018. Cited in: PMID: 40305722.","DOI":"10.1056\/NEJMc2501018"},{"key":"1832_CR47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-022-01328-x","volume":"15","author":"W Li","year":"2022","unstructured":"Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: Recent advances and future directions. J Hematol Oncol. 2022;15:110. https:\/\/doi.org\/10.1186\/s13045-022-01328-x Cited. In PMID: 35978372.","journal-title":"J Hematol Oncol."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01832-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01832-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01832-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:29:00Z","timestamp":1784593740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01832-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1832"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01832-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to the Declaration of Helsinki, all research described herein was approved by the Frankfurt Research Ethics Board (188\/15F). All patients have provided written informed consent as part of their protocols.","order":1,"name":"Ethics","label":"Ethics approval and consent to particpate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SS: consulting fees from AMGEN, Gilead, Pfizer, and SERB SAS, honoraria from the Akademie f\u00fcr Infektionsmedizin e.V., AMGEN, AVIR Pharma, CSi Hamburg GmbH, Gilead, Labor28, Novartis, Persberg Group GmbH\/DGIM e.V., Pfizer, and Vivantes GmbH, financial support for research projects from MorphoSys AG and Protherics Medicines Development Ltd, travel grants from AMGEN, Gilead, and Novartis. CDB: honoraria or travel support from Amgen, Gilead, Janssen, Novartis, Jazz, BMS, and Pfizer, contracted to carry out research for Novartis, the advisory board of Amgen. NG: Servier: Honoraria, Research Funding; Clinigen: Honoraria, Research Funding; Autolus: Honoraria; Incyte: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Novartis: Research Funding; Gilead: Honoraria, Research Funding; Amgen: Honoraria, Research Funding. MB: contracted to carry out research for Amgen; the advisory board of Amgen and Incyte, Speaker Bureau of Amgen, Johnson & Johnson, and Pfizer. The remaining authors declare no COI.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"52"}}